Alpha 2.0
Login Register
» Articles » PMID: 12201495

Phase II Trial of Arsenic Trioxide in Patients with Metastatic Renal Cell Carcinoma

Overview
Journal Invest New Drugs
Publisher Springer
Specialty Oncology
Date 2002 Aug 31
PMID 12201495
Citations 21
Authors
Jacqueline Vuky
Richard Yu
Lawrence Schwartz
Robert J Motzer
Affiliations
Soon will be listed here.
Abstract

Fourteen patients with metastatic renal cell carcinoma (RCC) were treated on a Phase II trial with arsenic trioxide (As2O3). Eligible patients had metastatic renal cell carcinoma with bidimensionally measurable disease, a Karnofsky performance status of at least 70%, life expectancy of greater than three months, and no evidence of brain metastases. Arsenic trioxide was given intravenously at a dose of 0.3 mg/kg/day for five consecutive days every four weeks. The most common toxicity observed was grade II elevation in liver function tests (36%), anemia (21%), renal insufficiency (14%), rash (7%), and diarrhea (7%). Best response was stable disease in 3 patients with one patient remaining on study at 8+ months At the dose and schedule used in this trial, arsenic trioxide did not achieve a complete or partial response in metastatic renal cell carcinoma.

Citing Articles

Phase I and pharmacodynamic study of arsenic trioxide plus radiotherapy in patients with newly diagnosed glioblastoma.

Ryu S, Ye X, Olson J, Mikkelsen T, Bangiyev L, Lesser G Neurooncol Adv. 2024; 6(1):vdae089.

PMID: 38978961 PMC: 11229030. DOI: 10.1093/noajnl/vdae089.

Heme Oxygenase-1 Inhibition Modulates Autophagy and Augments Arsenic Trioxide Cytotoxicity in Pancreatic Cancer Cells.

Ahmad I, Dafferner A, Salloom R, Abdalla M Biomedicines. 2023; 11(9).

PMID: 37761021 PMC: 10526552. DOI: 10.3390/biomedicines11092580.

The genomic landscape of sensitivity to arsenic trioxide uncovered by genome-wide CRISPR-Cas9 screening.

Chen J, Wang L, Luo X, Tang Y Front Oncol. 2023; 13:1178686.

PMID: 37251921 PMC: 10214836. DOI: 10.3389/fonc.2023.1178686.

Efficacy and Safety of the Arsenic Trioxide/Lipiodol Emulsion in the Transcatheter Arterial Chemoembolization Combined with Apatinib in the Treatment of Advanced Hepatocellular Carcinoma.

Li Z, Chen Q, Zhang W, Si G, Li J, Jiao D Can J Gastroenterol Hepatol. 2021; 2021:5565793.

PMID: 34458205 PMC: 8397569. DOI: 10.1155/2021/5565793.

Arsenic trioxide as a novel anti-glioma drug: a review.

Fang Y, Zhang Z Cell Mol Biol Lett. 2020; 25:44.

PMID: 32983240 PMC: 7517624. DOI: 10.1186/s11658-020-00236-7.

References
1.
Landis S, Murray T, Bolden S, Wingo P . Cancer statistics, 1998. CA Cancer J Clin. 1998; 48(1):6-29. DOI: 10.3322/canjclin.48.1.6. View
2.
Motzer R, Bander N, Nanus D . Renal-cell carcinoma. N Engl J Med. 1996; 335(12):865-75. DOI: 10.1056/NEJM199609193351207. View
3.
Niu C, Yan H, Yu T, Sun H, Liu J, Li X . Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood. 1999; 94(10):3315-24. View
4.
Chen G, Zhu J, Shi X, Ni J, Zhong H, Si G . In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins. Blood. 1996; 88(3):1052-61. View
5.
Chen G, Shi X, Tang W, Xiong S, Zhu J, Cai X . Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells. Blood. 1997; 89(9):3345-53. View